Actively Recruiting
Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-12-31
30
Participants Needed
1
Research Sites
549 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Observational, retrospective, prospective, single-center cohort study. Participation in the registry will be offered consecutively to any patient with the disease, newly diagnosed or with documented diagnosis made at another center, at any stage of the disease. Laboratory tests, imaging study for patient monitoring and care procedures all will be conducted in accordance with normal clinical practice.
CONDITIONS
Official Title
Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male gender
- Age 18 years or older
- Newly or previously diagnosed with CAH from 21-hydroxylase deficiency confirmed by CYP21A2 gene analysis
- Ability to provide informed consent
You will not qualify if you...
- Uncertain diagnosis of CAH
- CAH caused by or with co-presence of genetic alterations other than CYP21A2 mutations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
A
Alessandra Gambineri, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here